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【Objective】 To investigate the benefits and risks of
 
selenium supplementation in patients undergoing radio-
therapy.【Methods】 Studies on relationship between
 
selenium and radiotherapy in human trials were searched
 
on Pubmed electronic database. The keywords used
 
were“selenium”,“radiation”,“therapy”,“radiotherapy”
with probability OR as well as AND in MeSH term and
 
all field term. Only English language publications were
 
included.【Results】 16 studies of selenium and radio-
therapy in human trials were found after screening 154
 
articles on initial searching. Of 16 studies, 8 studies
(from 1998 to 2010)were selenium supplementation trials
 
in cancer patients who underwent radiotherapy. The
 
patients consisted of brain tumor patients,head and neck,
oral, cervical cancer patients and gynaecological tumor
 
patients. In all 8 studies,sodium selenite was used for
 
supplementation with range of dose 200-500μg daily per
 
oral  or 1000μg/day in physiological  saline. No
 
selenium toxicities were reported in all studies. Most
 
studies gave positive results such as improved general
 
condition, enhanced cell-mediated immune responsive-
ness,improved quality of life,reduced number and sever-
ity of diarrhea due to radiotherapy as well as reduced side
 
effect of radiotherapy.【Discussion】 Selenium sup-
plementation in the form of sodium selenite may offer
 
benefits for specific type of cancer patients undergoing
 
radiotherapy. At high concentration and long term use,
selenium can also be toxic. Further research and more
 
evidences of selenium supplementation for patients during
 
radiotherapy are required to clarify optimal dosing strat-
egies and the risks associated with supplementation.
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